MedDataX Logo

Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

NCT ID: NCT00192803

Last Updated: 2006-02-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan.

This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NIDDM

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

niddm ace2 NIDDM patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

ECT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

candesartan

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent
* Non-smokers
* Type II DM diagnosed patients
* Blood pressure \< 135/90
* Serum HbA1C \> 7%
* Serum creatinine \< 1mg%
* Urine microalbumin \< 300 mg/day
* Body mass index (BMI) \< 35 kg/m2

Exclusion Criteria

* Insulin-dependent diabetic patients
* Patient with persistent microalbuminuria
* Patient with history of severe hypertension
* Congestive heart failure
* Patient receiving renin-angiotensin-aldosterone system (RAAS)-related anti-hypertensive medications.
* Patient with major hepatic disease
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rambam Health Care Campus

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shlomo Keidar, MD

Role: PRINCIPAL_INVESTIGATOR

Rambam Health Care Campus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Internal Ward "A", Rambam Medical Center

Haifa, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shlomo Keidar, MD

Role: CONTACT

Phone: 97248542518

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ayelet Raz, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ACE2.CTIL

Identifier Type: -

Identifier Source: org_study_id